Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Principal Investigator: Ross, Maureen

(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)

Principal Investigator: Yau, Edwin H

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(ALTE1631) A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer

Principal Investigator: Rokitka, Denise A

A phase 2 trial of chemotherapy, Pembrolizumab and Propranolol in advanced esophageal/gastroesophageal junction adenocarcinoma patients.

Principal Investigator: Mukherjee, Sarbajit

Utilizing Patient Reported Quality of Life to Inform Patient Decision Making In Early Stage Lung Cancer

Principal Investigator: Singh, Anurag K

(APEC1621F) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF ENSARTINIB IN PATIENTS WITH TUMORS HARBORING ALK OR ROS1 GENOMIC ALTERATIONS

Principal Investigator: Twist, Clare J

ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Principal Investigator: McCarthy, Philip L

NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL
TRIAL EVALUATION (GUIDANCE)

Principal Investigator: Kuettel, Michael R

A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Principal Investigator: Iyer, Renuka V

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NRG-BN012)

Principal Investigator: Prasad, Dheerendra

(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic…

Principal Investigator: Barth, Matthew J

(ACNS1831) A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Principal Investigator: Barth, Matthew J

NRG-GU011: A PHASE II DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC
RADIOTHERAPY WITH OR WITHOUT ANDROGEN
DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE
CANCER (NRG PROMETHEAN)

Principal Investigator: Kuettel, Michael R

Phase II Randomized, Double Blind, Placebo-Controlled Trial of the Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers

Principal Investigator: Mahoney, Martin C

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)

Principal Investigator: Singh, Anurag K

S2015: Melanoma Margins Trial (MelMart): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1CM V 2CM Wide Excision Margins for Primary Cutaneous Melanoma

Principal Investigator: O'Brien, Shalana B

A Phase 1b/2, Dose-escalation, Randomized, Multi-Center Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma whose Disease has not Progressed on First Line FOLFIRINOX…

Principal Investigator: Fountzilas, Christos

Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma

Principal Investigator: Gupta, Ajay

(ARST2031) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO…

Principal Investigator: Gupta, Ajay

Improving Host Factors in Patients with Monoclonal Gammopathies

Principal Investigator: Hillengass, Jens

(COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Principal Investigator: Levine, Ellis G

: (S2012) Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Principal Investigator: Iyer, Renuka V

A randomized, parallel-group open-label trial of ENDS users switching from flavors of potentially high-toxicity profile to flavors of potentially low-toxicity profile (CRoFT_3.2)

Principal Investigator: Goniewicz, Maciej L

(PBTC-060) A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Principal Investigator: Twist, Clare J